AC Immune Reports Positive Interim Safety Data for ACI-24.060 in Down Syndrome Phase 1b/2 ABATE Trial
AC Immune reports positive interim safety data for ACI-24.060 in Down syndrome, showing no serious adverse events noted.Quiver AI SummaryAC Immune SA announced positive interim safety data from its Phase...
Why Shares of AC Immune Jumped This Week
The FDA has granted a Fast Track Designation to its Alzheimer's disease vaccine candidate.
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them